MarketInOut Stock Screener Log In | Sign Up
 

Eloxx Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/26/2026
Eloxx Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization41.24 mln
Float0.53 mln
Earnings Date08/14/2026

Piotroski F-Score

2 / 9
Weak

Relative Strength

23 / 100
Significantly lagging

Debt / Equity

-0.08
Negative equity

Dividend Yield

0.00%
No dividend

DPS

0.00
No dividend

Payout Ratio

0%
No payout

Business Description

Eloxx Pharmaceuticals is a clinical-stage drug development company headquartered in Arlington, Massachusetts, with operations in Israel and Australia. The company focuses on treatments for rare genetic diseases caused by nonsense mutations ? errors in genetic code that cause the body to stop producing essential proteins too early. Its lead drug candidate, ezutromid, is being tested in clinical trials for rare kidney conditions, while a separate compound is being developed with partner Almirall S.A. to treat serious inherited skin disorders.

Key Fundamentals

EPS-1.32
ROIC-39.28
ROA-145
EBITDA, mln-4.95
EV / EBITDA0.20
EV / EBIT0.20

Financial Strength

Piotroski F-Score 2 / 9
Short Ratio1.22
Short % of Float1.33

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -13.81% 8 / 100   
1 Month 6786% 100 / 100   
2 Months 12049900% 100 / 100   
6 Months 1204999936% 100 / 100   
1 Year 1081% 100 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us